These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 38066252

  • 1. The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer.
    Mamlins E, Scharbert L, Cardinale J, Krotov M, Winter E, Rathke H, Strodel B, Ankrah AO, Sathekge M, Haberkorn U, Kratochwil C, Giesel FL.
    Mol Imaging Biol; 2024 Feb; 26(1):81-89. PubMed ID: 38066252
    [Abstract] [Full Text] [Related]

  • 2. PSMA-GCK01: A Generator-Based 99mTc/188Re Theranostic Ligand for the Prostate-Specific Membrane Antigen.
    Cardinale J, Giesel FL, Wensky C, Rathke HG, Haberkorn U, Kratochwil C.
    J Nucl Med; 2023 Jul; 64(7):1069-1075. PubMed ID: 36759199
    [Abstract] [Full Text] [Related]

  • 3. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT.
    Ferro-Flores G, Luna-Gutiérrez M, Ocampo-García B, Santos-Cuevas C, Azorín-Vega E, Jiménez-Mancilla N, Orocio-Rodríguez E, Davanzo J, García-Pérez FO.
    Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Synthesis and Evaluation of 99mTc-Labeled PSMA-Targeted Tracers Based on the Lys-Urea-Aad Pharmacophore for Detecting Prostate Cancer with Single Photon Emission Computed Tomography.
    Lu K, Zhang C, Zhang Z, Kuo HT, Colpo N, Bénard F, Lin KS.
    Molecules; 2023 Jun 29; 28(13):. PubMed ID: 37446782
    [Abstract] [Full Text] [Related]

  • 7. 177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer.
    Santos-Cuevas C, Ferro-Flores G, García-Pérez FO, Jiménez-Mancilla N, Ramírez-Nava G, Ocampo-García B, Luna-Gutiérrez M, Azorín-Vega E, Davanzo J, Soldevilla-Gallardo I.
    Contrast Media Mol Imaging; 2018 Jun 29; 2018():5247153. PubMed ID: 30534027
    [Abstract] [Full Text] [Related]

  • 8. Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of 99mTc and 188Re Theranostic Agents for Prostate Cancer.
    Pham TT, Hungnes IN, Rivas C, Cleaver J, Firth G, Blower PJ, Sosabowski J, Cook GJR, Livieratos L, Young JD, Pringle PG, Ma MT.
    J Nucl Med; 2024 Jul 01; 65(7):1087-1094. PubMed ID: 38844360
    [Abstract] [Full Text] [Related]

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jul 01; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 10. 99mTc-HYNIC-(tricine/EDDA)-FROP peptide for MCF-7 breast tumor targeting and imaging.
    Ahmadpour S, Noaparast Z, Abedi SM, Hosseinimehr SJ.
    J Biomed Sci; 2018 Feb 19; 25(1):17. PubMed ID: 29455647
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
    Prostate; 2017 Aug 19; 77(11):1205-1212. PubMed ID: 28649735
    [Abstract] [Full Text] [Related]

  • 12. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
    Ortiz-Arzate Z, Santos-Cuevas CL, Ocampo-García BE, Ferro-Flores G, García-Becerra R, Estrada G, Gómez-Argumosa E, Izquierdo-Sánchez V.
    Nucl Med Commun; 2014 Apr 19; 35(4):423-32. PubMed ID: 24335877
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic Performance of 99mTc-iPSMA SPECT/CT in the Initial Staging of Patients with Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: A Comparative Analysis with 18F-PSMA-1007 PET/CT.
    Vargas-Ahumada JE, González-Rueda SD, Sinisterra-Solís FA, Casanova-Triviño P, Pitalúa-Cortés Q, Soldevilla-Gallardo I, Scavuzzo A, Jimenez-Ríos MA, García-Pérez FO.
    Cancers (Basel); 2023 Dec 13; 15(24):. PubMed ID: 38136369
    [Abstract] [Full Text] [Related]

  • 14. Development and Characterization of 99mTc-scFvD2B as a Potential Radiopharmaceutical for SPECT Imaging of Prostate Cancer.
    Bolzati C, Gobbi C, Ferro-Flores G, Turato S, Ocampo-Garcia B, Carpanese D, Marzano C, Spolaore B, Fracasso G, Rosato A, Meléndez-Alafort L.
    Int J Mol Sci; 2023 Dec 29; 25(1):. PubMed ID: 38203663
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of a New 99mTc-labeled GnRH Analogue as a Possible Imaging Agent for Prostate Cancer Detection.
    Farahani AM, Maleki F, Sadeghzadeh N, Abediankenari S, Abedi SM, Erfani M.
    Anticancer Agents Med Chem; 2020 Dec 29; 20(14):1695-1703. PubMed ID: 32560611
    [Abstract] [Full Text] [Related]

  • 16. 99m Tc-(EDDA/tricine)-HYNIC-GnRH analogue as a potential imaging probe for diagnosis of prostate cancer.
    Masteri Farahani A, Maleki F, Sadeghzadeh N, Abediankenari S, Abedi SM, Erfani M.
    Chem Biol Drug Des; 2020 Aug 29; 96(2):850-860. PubMed ID: 32279449
    [Abstract] [Full Text] [Related]

  • 17. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
    Kosowicz J, Mikołajczak R, Czepczyński R, Ziemnicka K, Gryczyńska M, Sowiński J.
    Cancer Biother Radiopharm; 2007 Oct 29; 22(5):613-28. PubMed ID: 17979564
    [Abstract] [Full Text] [Related]

  • 18. [Comparative study of the biodistribution of (99m)Tc-HYNIC-Lys3-Bombesin obtained with the EDDA/tricine and NA/tricine as coligands].
    Hernández-Cairo A, Perera-Pintado A, Prats-Capote A, Batista-Cuellar JF, Casacó-Santana C.
    Rev Esp Med Nucl Imagen Mol; 2012 Oct 29; 31(2):61-5. PubMed ID: 22305264
    [Abstract] [Full Text] [Related]

  • 19. Dosimetry estimation and preliminary clinical application of [99mTc]Tc-HYNIC-PSMA-XL-2 in prostate cancer.
    Yang H, Gao Z, Xu X, Liu C, Hu S, Zhang J, Song S.
    Ann Nucl Med; 2023 Jan 29; 37(1):60-69. PubMed ID: 36346503
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer.
    Zhang J, Zhang J, Xu X, Lu L, Hu S, Liu C, Cheng J, Song S, Zhang Y, Shi LQ.
    Sci Rep; 2020 Mar 06; 10(1):4179. PubMed ID: 32144340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.